Search Results - "Koper, Norbert P"

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study by Banerji, Udai, Prof, van Herpen, Carla M L, Prof, Saura, Cristina, MD, Thistlethwaite, Fiona, MD, Lord, Simon, MD, Moreno, Victor, MD, Macpherson, Iain R, MD, Boni, Valentina, MD, Rolfo, Christian, Prof, de Vries, Elisabeth G E, Prof, Rottey, Sylvie, Prof, Geenen, Jill, MD, Eskens, Ferry, MD, Gil-Martin, Marta, MD, Mommers, Ellen C, PhD, Koper, Norbert P, PhD, Aftimos, Philippe, MD

“…SummaryBackgroundTrastuzumab duocarmazine is a novel HER2-targeting antibody–drug conjugate comprised of trastuzumab covalently bound to a linker drug…”
Get full text

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results by Selmaj, Krzysztof, Barkhof, Frederik, Belova, Anna N, Wolf, Christian, van den Tweel, Evelyn RW, Oberyé, Janine JL, Mulder, Roel, Egging, David F, Koper, Norbert P, Cohen, Jeffrey A

“…Background: Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone® (GATE)…”
Get full text

Mutagen sensitivity in patients with familial and non‐familial urothelial cell carcinoma by Aben, Katja K.H., Cloos, Jacqueline, Koper, Norbert P., Braakhuis, Boudewijn J.M., Witjes, J. Alfred, Kiemeney, Lambertus A.L.M.

“…Due to variation in individual susceptibility, only a fraction of all individuals exposed to environmental carcinogens will develop cancer. Our aim was to…”
Get full text

Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography by Koper, N P, Thomas, C M, Massuger, L F, Segers, M F, Olthaar, A J, Verbeek, A L

“…Currently no available immunoassay system offers complete protection against spuriously elevated or lowered results due to interference by Human Anti-Mouse…”
Get more information

Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations by Massuger, Leon F.A.G., Koper, Norbert P., Thomas, Chris M.G., Dom, Koen E.L., Schijf, Charles P.T.

“…Staging of cervical cancer is routinely performed by means of examination under anesthesia in combination with radiographic and/or endoscopic techniques. This…”
Get full text

Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy by Koper, N P, Massuger, L F, Thomas, C M, Kiemeney, L A, Verbeek, A L

“…Most studies evaluating the role of serum CA 125 measurements in endometrial cancer report a positive correlation with prognostic factors. The present study…”
Get more information

Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in the Netherlands by Koper, Norbert P., Kiemeney, Lambertus A.L.M., Massuger, Leon F.A.G., Thomas, Chris M.G., Schijf, Charles P.T., Verbeek, André L.M.

“…To examine ovarian cancer incidence and mortality in the Netherlands, and to relate trends in mortality to changes in parity and use of oral contraceptives…”
Get full text

An illustration of the clinical relevance of detecting human antimouse antibody interference by affinity chromatography by Koper, Norbert P., Massuger, Leon F.A.G., Thomas, Chris M.G., Beyer, Cornelis, Crooy, Marinus J.

“…Elevated Cancer antigen 125 (CA 125) serum concentrations (up to 221 kU/l) were measured in a 39 year old woman with a positive family history of breast…”
Get full text

Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis by Koper, N P, Thomas, C M, Massuger, L F, Segers, M F, Kiemeney, L A, Verbeek, A L

“…Clinical management of ovarian cancer patients is facilitated by CA 125 determinations in serum. Presently, several assay systems based on different concepts…”
Get more information